globalnews.ca
93%
421
Johnson & Johnson’s single-dose COVID-19 vaccine candidate begins phase 3 trial
Johnson & Johnson is beginning a huge final study to try to prove if a single-dose COVID-19 vaccine can protect against the virus.The study starting Wednesday will be one of the world’s largest coronavirus vaccine studies so far, testing the shot in 60,000 volunteers in the U.S., South Africa, Argentina, Brazil, Chile, Colombia, Mexico and Peru.A handful of other vaccines in the U.S. — including shots made by Moderna Inc.